Latest Breaking News On - Homozygous familial hypercholesterolemia - Page 1 : comparemela.com

Ultragenyx Earnings: No Visible Path To Financial Success Yet (NASDAQ:RARE)

Ultragenyx Earnings: No Visible Path To Financial Success Yet (NASDAQ:RARE)
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

United kingdomEuropean commissionWay forwardHappy new yearHappy anniversarySly syndromeHomozygous familial hypercholesterolemiaSeeking alpha ratings summaryOrphan drug designationFast track designationGene transferOrnithine transcarbamylaseMediated gene transfer

Registry Reveals Sex Differences in HoFH Diagnosis, Treatment, and Cardiovascular Outcomes

Although the prevalence of myocardial infarction (MI) was doubled among men compared with women with homozygous familial hypercholesterolemia (HoFH), both sexes had similar ages at first MI.

Krung thep mahanakhonHofh international clinical collaboratorsClinical collaboratorsBangkok click studioHomozygous familial hypercholesterolemiaJama cardiologyMyocardial infarctionLow density lipoprotein

Ultragenyx Pharmaceutical Inc : Ultragenyx Receives Positive Recommendation from NICE in the U K for Evkeeza® - (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

Ultragenyx Pharmaceutical Inc : Ultragenyx Receives Positive Recommendation from NICE in the U K for Evkeeza® - (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesJules payneErik harrisCarolyn wangJoshua higaJaimini ceglaCardiovascular risk serviceRegulatory agencyNational institute for healthEuropean unionExchange commissionUltragenyx pharmaceutical incRegeneron pharmaceuticals incNational instituteCare excellence

Ultragenyx Receives Positive Recommendation from NICE in the U K for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

NOVATO, Calif., Jan. 04, 2024 Ultragenyx Pharmaceutical Inc. today announced that the National Institute for Health and Care Excellence has issued a final draft guidance recommending Evkeeza®.

United statesUnited kingdomJoshua higaJules payneErik harrisJaimini ceglaCarolyn wangEuropean unionNational institute for healthUltragenyx pharmaceutical incRegeneron pharmaceuticals incCardiovascular risk serviceExchange commissionRegulatory agencyNational instituteCare excellence

Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

For the first time, paediatric patients aged 5-11 years with HoFH in the EU have access to a first-in-class medicine to treat an ultrarare, inherited form of high cholesterolNOVATO, Calif., Dec. 18,.

Noord hollandUnited statesAlbert wiegmanJoshua higaCarolyn wangCommittee for medicinal products humanRegeneron pharmaceuticals incEu pressExchange commissionEuropean unionAmsterdam university medical centerUltragenyx pharmaceutical incDepartment of paediatricsEuropean commissionUniversity medicalMedicinal products